SARS-CoV-2

[Clinical Infectious Diseases] The Co-Stars study prospectively enrolled 3679 healthcare workers to comprehensively characterize the kinetics of SARS-CoV-2 spike (S), receptor-binding-domain (RBD) and nucleoprotein (N) antibodies in parallel. Participants screening seropositive had serial monthly serological testing for a maximum of 7 months with the Mesoscale Discovery Assay

[Nature Communications] To elucidate the immunopathology underlying COVID-19 severity, researchers perform cytokine and multiplex immune profiling in COVID-19 patients.

[Nature Communications] Researchers showed that treatment with the antiandrogen enzalutamide—a well-tolerated drug widely used in advanced prostate cancer—reducesd transmembrane serine protease 2 (TMPRSS2) levels in human lung cells and in mouse lung.

[Nature Reviews Gastroenterology & Hepatology] Data on the use of immunosuppressive and biologic therapies for gastrointestinal diseases is discussed with a primary focus on inflammatory bowel disease, autoimmune hepatitis and liver transplantation.

[Science Signaling] Investigators determined the x-ray structures of the SARS-CoV-2 2′-O-methyltransferase in complex with its reaction substrates, products, and divalent metal cations.

[Nature Communications] The efficacy of spike encoding mRNA vaccines against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls.